These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 19438776)
1. Does the type of ventricular assisted device influence survival, infection, and rejection rates following heart transplantation? Shuhaiber J; Hur K; Gibbons R J Card Surg; 2009; 24(3):250-5. PubMed ID: 19438776 [TBL] [Abstract][Full Text] [Related]
2. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659 [TBL] [Abstract][Full Text] [Related]
3. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167 [TBL] [Abstract][Full Text] [Related]
4. The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation. Bull DA; Reid BB; Selzman CH; Mesley R; Drakos S; Clayson S; Stoddard G; Gilbert E; Stehlik J; Bader F; Kfoury A; Budge D; Eckels DD; Fuller A; Renlund D; Patel AN J Thorac Cardiovasc Surg; 2010 Jul; 140(1):169-73. PubMed ID: 20451930 [TBL] [Abstract][Full Text] [Related]
5. Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival. Cleveland JC; Grover FL; Fullerton DA; Campbell DN; Mitchell MB; Lindenfeld J; Wolfel EE; Lowes BD; Shakar SF; Brieke A; Cannon A; Robertson AD J Thorac Cardiovasc Surg; 2008 Sep; 136(3):774-7. PubMed ID: 18805284 [TBL] [Abstract][Full Text] [Related]
6. Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy. Kirsch L; Timmermans T; Van Caenegem O; Gurne O; Noirhomme P; Jacquet LM; Latinne D; Poncelet AJ Eur J Cardiothorac Surg; 2008 Aug; 34(2):268-74; discussion 274. PubMed ID: 18456505 [TBL] [Abstract][Full Text] [Related]
7. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. Baran DA; Gass AL; Galin ID; Zucker MJ; Arroyo LH; Goldstein DJ; Prendergast T; Lubitz S; Courtney MC; Correa R; Chan M; Spielvogel D; Lansman SL J Heart Lung Transplant; 2005 Nov; 24(11):1886-90. PubMed ID: 16297796 [TBL] [Abstract][Full Text] [Related]
8. Clinical experience with the Novacor ventricular assist system. Bridge to transplantation and the transition to permanent application. McCarthy PM; Portner PM; Tobler HG; Starnes VA; Ramasamy N; Oyer PE J Thorac Cardiovasc Surg; 1991 Oct; 102(4):578-86; discussion 586-7. PubMed ID: 1921434 [TBL] [Abstract][Full Text] [Related]
9. Does continuous flow left ventricular assist device technology have a positive impact on outcome pretransplant and posttransplant? Klotz S; Stypmann J; Welp H; Schmid C; Drees G; Rukosujew A; Scheld HH Ann Thorac Surg; 2006 Nov; 82(5):1774-8. PubMed ID: 17062246 [TBL] [Abstract][Full Text] [Related]
10. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. Joyce DL; Southard RE; Torre-Amione G; Noon GP; Land GA; Loebe M J Heart Lung Transplant; 2005 Dec; 24(12):2054-9. PubMed ID: 16364849 [TBL] [Abstract][Full Text] [Related]
11. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Zierer A; Melby SJ; Voeller RK; Guthrie TJ; Ewald GA; Shelton K; Pasque MK; Moon MR; Damiano RJ; Moazami N Ann Thorac Surg; 2007 Aug; 84(2):515-20. PubMed ID: 17643627 [TBL] [Abstract][Full Text] [Related]
12. Posttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices. Russo MJ; Hong KN; Davies RR; Chen JM; Sorabella RA; Ascheim DD; Williams MR; Gelijns AC; Stewart AS; Argenziano M; Naka Y J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1425-32.e1-3. PubMed ID: 19931672 [TBL] [Abstract][Full Text] [Related]
17. Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation. Thoratec Ventricular Assist Device Principal Investigators. Farrar DJ J Heart Lung Transplant; 1994; 13(1 Pt 1):93-100; discussion 100-1. PubMed ID: 8167132 [TBL] [Abstract][Full Text] [Related]
18. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Patel ND; Weiss ES; Schaffer J; Ullrich SL; Rivard DC; Shah AS; Russell SD; Conte JV Ann Thorac Surg; 2008 Sep; 86(3):832-40; discussion 832-40. PubMed ID: 18721570 [TBL] [Abstract][Full Text] [Related]
19. Differential impact on post-transplant outcomes between pulsatile- and continuous-flow left ventricular assist devices. Ventura PA; Alharethi R; Budge D; Reid BB; Horne BD; Mason NO; Stoker S; Caine WT; Rasmusson B; Doty J; Clayson SE; Kfoury AG Clin Transplant; 2011; 25(4):E390-5. PubMed ID: 21401721 [TBL] [Abstract][Full Text] [Related]
20. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). Starling RC; Naka Y; Boyle AJ; Gonzalez-Stawinski G; John R; Jorde U; Russell SD; Conte JV; Aaronson KD; McGee EC; Cotts WG; DeNofrio D; Pham DT; Farrar DJ; Pagani FD J Am Coll Cardiol; 2011 May; 57(19):1890-8. PubMed ID: 21545946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]